Tata in discussion with Moderna to launch COVID-19 vaccine in India

Published On 2021-01-25 08:44 GMT   |   Update On 2021-01-25 08:44 GMT
Advertisement

New Delhi: Tata Group's healthcare venture is said to have started initial discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India, the Economic Times reported on Monday.

Tata Medical & Diagnostics could team up with the India's Council of Scientific and Industrial Research to carry out clinical trials of Moderna's vaccine candidate in India, the report said, citing officials familiar with the matter.

Advertisement

Moderna did not respond to Reuters request for a comment outside business hours, while Tata Medical & Diagnostics did not immediately respond.

Unlike Pfizer's vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited.

Data released in November from Moderna's late-stage study showed it was 94.1% effective with no serious safety concerns. The shot was approved for use in the United States in December and in Europe earlier this month.

India mandates that any vaccine maker must conduct an additional local study if it has to be considered for what the country calls the world's biggest vaccination programme.

It gave emergency-use approval to a vaccine by Bharat Biotech and state-run Indian Council of Medical Research and another licensed from Oxford University and AstraZeneca that is being produced by the Serum Institute.

India has the world's second highest COVID-19 caseload after the United States, but daily cases have been declining since hitting a peak in September.

India's drugs controller has said the overall efficacy of the AstraZeneca vaccine, locally branded COVISHIELD, was 70.42% based on trials done overseas, but the approval for Bharat Biotech's COVAXIN has faced criticism due to the lack of efficacy data.


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News